SCHEMBL381502

SCHEMBL381502

CSC(SC)=C(C#N)C#N

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.34
XBP1 P17861 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774709 0.71 ALDH1A1 (0.33) ALDH1A1MAPTHPGDRAB9A
SCHEMBL13404953 0.71
SCHEMBL23635286 0.71
SCHEMBL6905336 0.69
SCHEMBL8281797 0.69
SCHEMBL11222290 0.69
SCHEMBL9710760 0.67 ALDH1A1 (0.45) ALDH1A1MAPTHPGDTDP1
SCHEMBL9710754 0.67 ALDH1A1 (0.45) ALDH1A1MAPTHPGDTDP1
SCHEMBL11749101 0.67 ALDH1A1 (0.32) ALDH1A1TDP1
SCHEMBL6795993 0.67 ALDH1A1 (0.35) ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025199601-A1 BIODEGRADABLE POLYMERIC MICRO- AND NANO-PARTICLES AND USE THEREOF BIOBEADS SOLUÇÃO EM POLÍMEROS LTDA (BR) 2025-10-02 WO claimed
CN-114512719-B Eutectic solvent-based electrolyte and application thereof 中国科学院青岛生物能源与过程研究所 2024-12-03 CN claimed
CN-115433212-A Biphenyl compound as immunomodulator and preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-12-06 CN claimed
CN-114512719-A Eutectic solvent-based electrolyte and application thereof 中国科学院青岛生物能源与过程研究所 2022-05-17 CN claimed
CN-105886476-B Compositions and methods for enhancing viral potency 渥太华医院研究所 2020-02-18 CN claimed
US-9283254-B2 Compositions and methods for enhancing virus efficacy OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2016-03-15 US claimed
US-20150202240-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2015-07-23 US claimed
EP-2872507-A1 AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2015-05-20 EP claimed
US-8940291-B2 Compositions and methods for enhancing virus efficacy OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2015-01-27 US claimed
US-8835420-B2 Azaindole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-16 US claimed
WO-2014011568-A1 AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-16 WO claimed
US-20140018344-A1 AZAINDOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-16 US claimed
US-20120134963-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2012-05-31 US claimed
EP-2451795-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY Ottawa Hospital Research Institute (CA) 2012-05-16 EP claimed
WO-2011003191-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2011-01-13 WO claimed
JP-61130333-A None JP disclosed
US-12577247-B2 Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist Bugworks Research, Inc. (US) 2026-03-17 US disclosed
US-4057416-A 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides FMC CORPORATION (US) 1977-11-08 US disclosed
US-4028089-A BENZOXAZOLINYLIDENE-MALONITRILE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 1977-06-07 US disclosed
US-4013769-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134963-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY HAVCR2, MAVS, TSG101 ALDH1A1 4516/4885MAPT 3295/4885HPGD 4466/4885
US-20150202240-A1 COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY HAVCR2, MAVS, TSG101 ALDH1A1 4516/4885MAPT 3295/4885HPGD 4466/4885
US-12577247-B2 Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist ADORA1, ADORA3, ADORA2A ALDH1A1 316/4885MAPT 3965/4885HPGD 3047/4885
US-20140018344-A1 AZAINDOLE DERIVATIVES PIK3R5, PIK3R1, PIK3R2 ALDH1A1 1597/4885MAPT 4736/4885HPGD 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.